Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to quiet MS brain lesions

NCT ID NCT06220669

Ongoing Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests an experimental drug called LY3541860 against a placebo in 63 adults with relapsing multiple sclerosis. The goal is to see if the drug can slow the appearance of new brain lesions seen on MRI scans. The study lasts about 9 months, with an additional 6 months of follow-up.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
LY3541860 (an experimental drug given by IV)
What this could lead to
If it works, this could point toward a new treatment that reduces brain lesion activity in people with relapsing multiple sclerosis.
What could go wrong
This is an early Phase 2 trial with only 63 participants, so results may not apply to everyone. The drug may not slow lesions better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

  • Centre Hospitalier Intercommunal - Site de Poissy

    Poissy, 78303, France

  • Clinirem

    Lublin, 20-064, Poland

  • Conquest Research LLC - Winter Park - ClinEdge - PPDS

    Winter Park, Florida, 32789, United States

  • Consultants in Neurology

    Northbrook, Illinois, 60062, United States

  • ETG Neuroscience - PPDS

    Warsaw, 02-677, Poland

  • Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta-VIA MANGIAGALLI 3

    Milan, 20133, Italy

  • Hope Neurology

    Knoxville, Tennessee, 37922, United States

  • IBISMED Wielospecjalistyczne Centrum Medyczne

    Zabrze, 41-800, Poland

  • M.A. - LEK A.M. Maciejowscy SC. Centrum Terapii SM

    Katowice, 40-571, Poland

  • NEURO-MEDIC Sp. z o. o.

    Katowice, 40-686, Poland

  • Nemocnica Ruzinov

    Bratislava, 826 06, Slovakia

  • Neurocentrum Bydgoszcz sp. z o.o.

    Bydgoszcz, 85-796, Poland

  • Niepubliczny Zaklad Opieki Zdrowotnej NEURO-KARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy

    Poznan, 61-853, Poland

  • Panhandle Research and Medical Clinic

    Gulf Breeze, Florida, 32561, United States

  • Pauls Stradins Clinical Univeristy Hospital

    Riga, LV-1002, Latvia

  • Premier Neurology

    Greer, South Carolina, 29605, United States

  • ProNeuro Centrum Medyczne

    Żory, 44-240, Poland

  • Queen's Medical Centre

    Nottingham, NG7 2UH, United Kingdom

  • Sharlin Health and Neurology

    Ozark, Missouri, 65721-5315, United States

  • Specjalistyczna Praktyka Lekarska prof. Grzegorz Opala

    Katowice, 40-060, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.